SpeakEasy Announces New Chief Scientific Officer

Published: May 30, 2019

SpeakEasy Announces New Chief Scientific Officer

SpeakEasy Cannabis Club Ltd. announced the addition of Frey Garabagi as its newly appointed Chief Scientific Officer and to the Company’s Board of Directors. Mr. Garabagi’s distinguished career includes a degree in the field of plant molecular genetics and biotechnology, with 10 years of post-doctoral research experience from the University of Guelph. Frey held the position of Vice President of Research and Quality Affairs at Emerald Health Therapeutics Inc. as a research scientist, and inventor from September 2015 to January 2019.

Mr. Garabagi currently holds full security clearance and is actively involved in various cannabis related projects such as breeding, strain characterization, product development, extraction technologies and development of cannabis oil formulations, preclinical pharmacokinetic studies, and cannabis genetics. In 2012, Frey founded Herbaceous Inc., a company that organized preclinical research with non-psychoactive cannabinoids on epilepsy and obesity. The Company received its right-to-build letter from Health Canada in February 2014, and secured $6 M investment capital for building its facility in 2015.

“I am extremely pleased to announce Mr. Garabagi’s appointment as SpeakEasy’s new Chief Scientific Officer. Mr. Garabagi is an incredible, well respected visionary in the cannabis industry as a whole,” said Marc Geen. “Frey will be furthering SpeakEasy’s journey as an important and innovative Company in this life changing industry. Mr. Garabagi is the first of many positive changes to the Board and the executive team of SpeakEasy in the near future,” further states Marc Geen.

In connection with his Employment Agreement, Mr. Garabagi is entitled to receive, in addition to his salary and in accordance with applicable laws (including the policies of the Canadian Securities Exchange (the “CSE”), incentive stock options and a signing bonus payable by the issuance of common shares in the capital of SpeakEasy. The Company’s Board of Directors has approved the grant of an option for up to 100,000 common shares of the Company with an exercise price of $0.86/share. The option will expire 5 years from the date of grant.